Boston Scientific/$BSX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Boston Scientific
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
- Ticker
- $BSX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 59,000
- Headquarters
- Marlborough, United States
- Website
- www.bostonscientific.com
BSX Metrics
BasicAdvanced
$67B
18.64
$2.47
0.57
-
Price and volume
Market cap
$67B
Beta
0.57
52-week high
$105.65
52-week low
$41.39
Average daily volume
18M
Financial strength
Current ratio
1.24
Quick ratio
0.558
Long term debt to equity
0.434
Total debt to equity
0.423
Interest coverage (TTM)
11.89%
Profitability
EBITDA (TTM)
5,726
Gross margin (TTM)
69.19%
Net profit margin (TTM)
17.50%
Operating margin (TTM)
20.47%
Effective tax rate (TTM)
5.00%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
6.19%
Return on equity (TTM)
15.34%
Valuation
Price to earnings (TTM)
18.642
Price to revenue (TTM)
3.243
Price to book
2.67
Price to tangible book (TTM)
255.17
Price to free cash flow (TTM)
18.784
Free cash flow yield (TTM)
5.32%
Free cash flow per share (TTM)
2.449
Growth
Revenue change (TTM)
13.53%
Earnings per share change (TTM)
46.89%
3-year revenue growth (CAGR)
16.15%
10-year revenue growth (CAGR)
10.30%
3-year earnings per share growth (CAGR)
60.29%
10-year earnings per share growth (CAGR)
25.45%
What the Analysts think about BSX
Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.
Analyst projections of the future price of Boston Scientific stock.
Bulls say / Bears say
Second-quarter organic sales rose 7% and adjusted EPS of $0.86 beat the company’s $0.82–$0.84 guidance range. Both Cardiovascular and MedSurg grew, showing the wider business is still expanding despite pressure in key franchises. (PR Newswire)
A pivotal FARAPULSE trial met its safety and effectiveness endpoints and outperformed anti-arrhythmic drugs in patients with persistent atrial fibrillation. If the findings support wider adoption, the platform could reach patients beyond its established use. (Boston Scientific)
The SEISMIQ coronary lithotripsy study met its primary safety and effectiveness endpoints in patients with severely calcified arteries. The results support a regulatory submission and give Boston Scientific a potential route into a growing treatment area. (Boston Scientific)
Boston Scientific cut its 2026 organic sales growth outlook to 5%–6% and lowered its adjusted EPS forecast after cutting both earlier in the year. Management said the pressure could continue into 2027, leaving less near-term earnings momentum. (Reuters)
WATCHMAN demand has slowed sharply, with clinical evidence affecting referral patterns and standalone procedures weakening. Management expects global WATCHMAN sales to decline in the second half, putting pressure on a major growth franchise. (Reuters)
Boston Scientific has lost share in the competitive U.S. electrophysiology market, where rivals are challenging its pulsed-field ablation business. Management expects this pressure to persist into 2027, so the company may struggle to regain its earlier growth rate. (MedTech Dive)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
BSX Financial Performance
Revenues and expenses
BSX Earnings Performance
Company profitability
Upcoming events
No upcoming events
BSX News
AllArticlesVideos
Funds containing BSX
AllUSDEURGBP
Fund name | Fund size | $BSX weighting |
|---|---|---|
iShares AI Adopters and Applications£AIAA | $188M | 1.22% |
iShares AI Adopters and Applications€AIAA | $188M | 1.22% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 1.10% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 1.10% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.